FAST NEWS: Innovent Bio’s loss narrows on strong sales growth
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced Wednesday its annual net loss last year narrowed 52.8% year-over-year to 1.03 billion yuan ($143 million), while its non-GAAP net narrowed by an even…
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
FAST NEWS: Zai Lab’s loss narrows on growing revenue
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
FAST NEWS: CStone says CEO to boost company holdings
The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of its enlarged share capital, to raise about HK$2.36 billion ($302 million).…
I-Mab gets new CEO after long search. Sale of the company coming next?
The drug developer filled an 18-month-long vacuum in its top position by appointing an industry veteran with a history of deal-making as its new CEO Key Takeaways: I-Mab has appointed…
Recent Articles
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
9688.HK
ZLAB.US
FAST NEWS: Zai Lab’s loss narrows on growing revenue
ZLAB.US
9688.HK
RELATED ARTICLES
-
FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales
1801.HK -
FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement
1801.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
